ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.

About Climb Bio, Inc.

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit .

Investors

Chris Brinzey

ICR Westwicke



339-970-2843

Media

Jon Yu

ICR Westwicke



475-395-5375



EN
04/10/2024

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at William Blair’s Upcoming Conference Event on T...

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024. About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutu...

October 4, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Host Virtual Investor Event on October 15, 2024

Climb Bio to Host Virtual Investor Event on October 15, 2024 WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases. Climb Bio’s virtual investor event will include presentations from Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, Stephen...

October 3, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Eliem Therapeutics Announces Rebranding and Corporate Name Change to C...

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. Name change to "Climb Bio" marks the Company’s transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective October 3rd WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that it will change its corporate name to Climb Bio, Inc. The new name and corporate brand reflect the Company’s new mission to develop a pipeline focused on immune-mediated diseases,...

October 2, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunolog...

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024. Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Format: 1x1 meetings About Eliem Therapeutics, Inc.Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, incl...

September 11, 2024 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Announces Additions to its Leadership Team Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: ELYM), announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. “I am delighted to announce the addition of Brett and Nishi to our executive team,” said Dr. Aoife Brennan, CEO of Eliem Therapeutics. “Since completin...

August 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch